Foamix Pharmaceuticals Ltd. (FOMX) Stock News
NASDAQ:FOMX - Nasdaq -
FOMX Latest News, Press Relases and Analysis
Menlo's partner LEO Pharma remedies Finacea Foam supply issues
Menlo Therapeutics' (NASDAQ:MNLO) wholly owned subsidiary, Foamix Pharmaceuticals (NASDAQ:FOMX) has entered into a settlement and license agreement to resolve the remaining pending patent litigation
Mentions: MNLO
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Mentions: MNLO
Menlo Therapeutics up 20% ahead of Foamix merger & key data readout
Thinly traded micro cap Menlo Therapeutics (MNLO +20%) is one of the few issues in the green today, up on more than triple normal volume, ahead of the expected March 9 close of its previously announce
Mentions: MNLO
Stocks That Hit 52-Week Highs On Thursday
During Thursday's morning session, 405 companies made new 52-week highs. Significant Points: MACOM Technology (NASDAQ: MTSI) was the largest firm on a market cap...
FOAMIX PHARMACEUTICALS LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) Acceleron Pharma Inc (...
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Shareholders back Foamix/Menlo tie-up
Holders of stock in Foamix Pharmaceuticals (FOMX +3.9%) and Menlo Therapeutics (MNLO +2.1%) have voted in favor of the merger announced three months ago.After the consummation of the tie-up, expected
Mentions: MNLO
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Best & Worst Performing Small Cap Stocks for January 15, 2020
CETX – CETX leads the way today as the best performing small cap stock, closing up 54.24%.
Foamix Pharma's Amzeeq on preferred list at Express Scripts
Foamix Pharmaceuticals (NASDAQ:FOMX) is up 5% premarket on light volume in reaction to its announcement that acne med Amzeeq (minocycline) topical foam, 4% is now on Express Scripts' National Preferre
Mentions: GM
Foamix up 7% on U.S. acne foam launch
Foamix Pharmaceuticals (FOMX +7%) is up on below-average volume on the heels of its announcement that acne treatment Amzeeq (minocycline) topical foam, 4% is now available in U.S. pharmacies for patie
Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam
URGENT NEWS: Monteverde & Associates PC Announces an Investigation of FOAMIX PHARMACEUTICALS LTD - FOMX
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.
Mentions: MNLO